According to FutureWise analysis the Corneal Implant Market in 2025 is US$ 1.40 billion, and is expected to reach US$ 2.13 billion by 2033 at a CAGR of 5.39%. The growth of the market is largely fueled by the increasing occurrence of corneal diseases, including conditions like keratoconus and Fuchs’ dystrophy.Advancements in transplant techniques and the adoption of synthetic and bioengineered implants are improving patient outcomes and expanding treatment acceptance.
Corneal Implant is a step that is between contact lenses and a corneal transplant. Corneal implants are mainly used for the treatment of keratoconus, it’s a degenerative disorder of the eye in which the cornea thins and becomes a more conical shape rather than a normal gradual curve. Corneal implants are designed for long term vision with numerous advantages includes outpatient procedure, less invasive than a corneal transplant. There are different types of corneal implants are available which includes refractive corneal implants, corneal reshaping, and small aperture implants.
Increasing prevalence of corneal ulcers, infection, and keratoconus is expected to boost the growth of the market. Additionally, increasing incidence of genetic disorders like fuch’s dystrophy is expected to fuel the growth. Further, increasing adoption of corneal transplantation in primary healthcare settings and awareness among the general population is expected to boost the growth of corneal implant market. Along with this, increased per capita healthcare expenditure of the general population is expected to increase the adoption of implants. Recent advances in medical technologies further decreased the complication of traditional methods and improved adoption. It also decreased medical errors and increased the success rate of transplantation.
Bioengineered Corneas: Researchers at AIIMS and IIT Delhi have developed bioengineered corneas using tissue from donor corneas that were previously considered unfit for transplantation. These corneas are carefully processed to eliminate all cells and infections, resulting in a clean scaffold that integrates with the recipients' eyes. This innovative approach has shown promising results in animal testing and is currently undergoing clinical trials at AIIMS.